How to Earn an 86% Gain in Just 1 Hour

Check out this chart …

At one point, this stock was up 86.8% in just over an hour. 

This is what happened to MindMed (NASDAQ: MNMD) on Wednesday after it was announced that the company had received breakthrough designation status from the FDA for its treatment for generalized anxiety disorder.

If you’re unfamiliar, the FDA grants breakthrough status for drugs that treat life-threatening conditions, and clinical evidence shows that those drugs demonstrate substantial improvement over currently available treatments. 

What makes this particularly interesting, however, is that MindMed’s new medication is an EN-23 medication.

I literally just told you about EN-23 on Friday, writing …

EN-23 is a valuable class of molecules that drastically improves brain function.  It’s actually one of the biggest breakthroughs medical science has seen in 50 years, because not only can it treat mental health conditions such as depression, anxiety, PTSD and addiction, it also has the ability to help you lose weight, treat chronic pain and even extend your lifespan by up to 20 years.

While EN-23 isn’t necessarily new, the FDA is expected to approve the nation’s first EN-23 medication in August developed by company called Lykos Therapeutics. This company has developed a new and incredibly effective treatment for PTSD.

That company isn’t public, but there are a number of other EN-23 companies that are. Three in particular are actively working with the FDA to get their own EN-23 therapies through clinical trials and ultimately out into the market. 

I wrote about those companies in a recent investment note, which you can access here.

Truth is, I’ve been following the EN-23 space for nearly ten years now.  

I’ve been watching it grow from little more than a big idea to a market that’s producing what could easily be the most profitable drug in human history.

It could quite literally replace …

• The alcohol treatment market — currently valued at $35 billion.
• The PTSD treatment market — currently valued at around $90 billion
• The market for diabetes treatments — estimated to be worth about $16.4 billion 
• The smoking cessation market — currently valued at $39 billion.
• The anti-aging drug market — currently valued at $54 billion.
• The neurodegenerative disease treatment market — currently valued at $40 billion
• The depression treatment market — currently valued at $150 billion
• The sexual enhancement drug market —currently valued at $10 billion
• The market for anorexia treatments — valued at $2.1 billion
• The market for treating chronic pain — valued at $635 billion

Just those 10 markets alone, you’re looking at more than $1 trillion up for grabs.

And the FDA is fast-tracking the approval of EN-23! 

Now at the moment, there are two EN-23 companies in particular that are next in line for breakthrough status designation from the FDA.  And when that happens, expect to see the same result we saw last week with MindMed.

Here it is again, just as a reminder …

Don’t sleep on this opportunity.

The FDA is literally giving us all the intel we need to make a ton of cash from its move to fast-track new EN-23 medications that are on the cusp of FDA approval. 

And these are the EN-23 companies you want to own now — before that happens.

To a new way of life and a new generation of wealth…

Jeff Siegel

Check us out on YouTube!

@JeffSiegel on Twitter

Jeff is a contributing analyst for New World Assets. For more on Jeff, go to his editor’s page.